恆指跌幅曾擴至近240點失守二萬八 醫藥股捱沽 藥明生物續挫逾6%
歐元區6月綜合產出指數終值意外上修續升至59.5創15年高，加上英國首相宣佈兩週後解除所有防疫限制措施。歐洲主要股市全面反覆升0.1%-0.6%。此外，美股昨晚假期休市，但道指期貨續升近0.2%報34,740，標普期貨續升2點報4,345；但納指期貨微吐不足0.1%報14,701。
亞太區股市今天普遍造好，但升幅均少於0.5%，其中臺灣加權指數曾越萬八關屢創紀錄高。不過，中港及新西蘭股市受壓。
港股六連跌，今早在藥明生物(02269.HK)/申洲(02313.HK)開1%-1.5%及騰訊(00700.HK)和阿裏巴巴(09988.HK)偏軟拖累，恆指低開6點報28,136，跌幅曾擴至238點，低見27,904，爲5月中旬以來最低，現造27,956，續跌187點或近0.7%，成交額256億元。
藍籌股普遍向下，藥明生物由收市紀錄高位連跌第五天，承昨天失守10天線勢，今早進一步跌破20天線(131.65元)，最低見128.6元，現造129.73，續挫6%；阿裏健康(00241.HK)五連跌兼創逾14個月低，最低見15.42元，現造15.48元，跌4.4%；石藥(01093.HK)五連跌兼失守百天線(10元)，報9.82元，跌5%；中生製藥(01177.HK)五連跌，最低見7.13元，創近半年低，現造7.16元，跌2.3%。
信義光能(00968.HK)跌破20天線(15.1元)，最低見14.8元，現造14.96元，跌4.3%。申洲及舜宇(02382.HK)跌幅擴至逾2%，分別報188.5元及237.2元，前者失守20天線(191.6元)，後者失守10天線(238.5元)。美團(03690.HK)承昨天失守牛熊線勢，今早續跌2%報281.1元。
吉利(00175.HK)及蒙牛(02319.HK)回吐逾1.5%-2%，分別報24.15元及44.9元。不過，匯控(00005.HK)、國壽(02628.HK)及中國平安(02318.HK)微升0.3%-0.7%，前者報45.3元，後者報74.3元；港交所(00388.HK)升1.4%報462元。此外，中海油(00883.HK)升1%報9.08元；海底撈(06862.HK)升4.9%報42.9元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
